Purchase of 600,000 shares of Series B Preferred Stock under a Securities Purchase Agreement, initially convertible into 3,000,000 shares of common stock.
| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Patrick Mercer
Also a director
President, Chief Executive Officer and Chief Operating Officer
|
54 | Not stated | Not stated | Not reported | |
|
Romeo Dizon
Chief Financial Officer
|
68 |
Since 2025
1 year
|
Not stated | Not reported | |
|
Bassem BouHabib
Senior Vice President of International Sales and Business Development
|
50 |
Since 2026
this year
|
2012 | $550,834 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Purchase of 600,000 shares of Series B Preferred Stock under a Securities Purchase Agreement, initially convertible into 3,000,000 shares of common stock.
Initial convertible promissory note issued to Novel under a Note Purchase Agreement, with a 36-month term and 12% interest.
Investor Rights Agreement with Novel granting registration rights, a right to appoint two Board members, and approval rights over certain corporate actions.
Board appointment of William Moore and Nick Chen pursuant to the Investor Rights Agreement with Novel, later elected at the 2025 Annual Meeting.
Loading...